Company Overview and News

3
China casts shadow over new US LNG terminals with tariff

2018-09-18 theedgemarkets
LONDON (Sept 18): China set a tariff on US liquefied natural gas (LNG), casting a shadow over US plans for new export terminals that were expected to turn the United States into the world's second largest LNG seller.
CQP KMI LNG TRI GLNG KMR CVB KMRFZ

3
China casts shadow over new U.S. LNG terminals with tariff

2018-09-18 reuters
LONDON (Reuters) - China set a tariff on U.S. liquefied natural gas (LNG), casting a shadow over U.S. plans for new export terminals that were expected to turn the United States into the world’s second largest LNG seller.
CQP KMI LNG GLNG KMR CVB KMRFZ LNG

3
China sets tariff on U.S. LNG just as exports ramp up

2018-09-18 reuters
(Reuters) - China has set a 10 percent tariff on imports of U.S. liquefied natural gas just as trade of the super-chilled fuel between the two nations started to ramp up and exports from new terminals on the U.S. Gulf Coast are poised to begin.
CQP KMI LNG KMR KMRFZ CVB

8
Kinder Morgan: Growth Projects To Boost Dividend

2018-09-17 seekingalpha
Kinder Morgan is the largest midstream company in North America, meaning that it benefits from the positive trends affecting the industry.
DCP APA KMI KMR TRGP KMRFZ CVB

2
Kinder Morgan to Divest Canadian Assets, Hires TD Securities

2018-09-17 zacks
Kinder Morgan Inc (KMI - Free Report) has reportedly hired investment bank, TD Securities, for the scheduled sale of its Canadian business. The sale, which will indicate the U.S. pipeline giant’s exit from Canada, is expected to raise about C$2.4 billion ($1.8 billion). At a conference in September, Kinder Morgan’s chief executive expressed intent in divesting the remaining Canadian business, which was initially purchased to support the Trans Mountain project.
ENBBF MEG ENB ENB KMI MEGEF EBBNF BIP KMR CVB KMRFZ

6
3 Energy Stocks

2018-09-17 seekingalpha
Royal Dutch Shell's dividend has been flat for 18 quarters, but the company has implemented a new strategy.
ENBBF RDS.B RDS.A XOM RDSB ENB EPD RDSA SE ENB HP KMI RYDBF EBBNF RYDAF KMR CVB KMRFZ

1
Kinder Morgan reopens South Carolina Fuel Terminals after Florence

2018-09-16 reuters
NEW YORK, Sept 16 (Reuters) - Kinder Morgan Inc reopened fuel terminals in South Carolina on Sunday after Tropical Storm Florence passed through the area, a spokeswoman said in a statement.
KMI KMR KMRFZ CVB

9
Hurricane Florence Could Send Coal Prices Soaring

2018-09-16 oilprice
MINING.com is a web-based global mining publication focusing on news and commentary about mining and mineral exploration. The site is a one-stop-shop for mining industry…
ACIIQ DUKH ACI KMI DUK ARCH CNTE KMR KMRFZ CVB

11
6 Monthly Dividend Stocks to Buy

2018-09-14 investorplace - 1
Most dividend stocks pay their shareholders quarterly, but a few dividend yielding stocks offer monthly distributions.
SJR.B WBA LTC SJRWF OPRF SJR.A KMI PAA KMR STAG CVB APLE O SJR FDX MAR HLT PBA KMRFZ

2
UPDATE 2-Kinder Morgan hires TD to sell Canadian business -sources

2018-09-14 reuters
TORONTO/NEW YORK (Reuters) - Kinder Morgan Inc (KMI.N) has hired investment bank TD Securities (TD.TO) to facilitate a potential sale of its Canadian business, which could fetch as much as C$2.4 billion ($1.8 billion), people familiar with the situation told Reuters this week.
ENBBF KML MEG ENB ENB KMI MEGEF EBBNF BIP KMR CVB KMRFZ

1
UPDATE 1-Kinder Morgan hires TD to sell Canadian business -sources

2018-09-14 reuters
TORONTO/NEW YORK, Sept 14 (Reuters) - Kinder Morgan Inc has hired investment bank TD Securities to facilitate a potential sale of its Canadian business, which could fetch the U.S. pipeline operator as much as C$2.4 billion ($1.8 billion), people familiar with the situation told Reuters this week.
KMI KMR KMRFZ CVB

1
Kinder Morgan hires TD to sell Canadian business - sources

2018-09-14 reuters
TORONTO/NEW YORK, Sept 14 (Reuters) - Kinder Morgan Inc has hired investment bank TD Securities to facilitate a potential sale of its Canadian business, which could fetch the U.S. pipeline operator as much as C$2.4 billion ($1.8 billion), people familiar with the situation told Reuters this week.
KMI KMR KMRFZ CVB

29
Top Stock Reports for JPMorgan, Mastercard & AbbVie

2018-09-14 zacks
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Mastercard (MA) and AbbVie (ABBV). These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
STQN MA CVS BRK.A KMI ABBV OXY KMR KMRFZ CVB ABBV

1
Canada’s Environment Minister: No Apologies For Oil Industry Support

2018-09-14 oilprice
Irina is a writer for the U.S.-based Divergente LLC consulting firm with over a decade of experience writing on the oil and gas industry.
KMI KMR KMRFZ CVB

1
Why Hold Strategy is Apt for Kinder Morgan (KMI) Stock Now

2018-09-14 zacks
We issued an updated research report on Kinder Morgan, Inc. (KMI - Free Report) on Sep 14. The company’s midstream properties are linked to all natural gas-rich plays in the United States. However, the company’s balance sheet is more levered than the industry.
HLX TCP CY KMI KMR KMRFZ CVB

Related Articles

DMPI: DelMar Pharmaceuticals Analysis and Research Report

19h - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

CUSIP: 49455U100